在可手术的乳腺癌中,用聚基-聚氨基酸 (Polya.Polyu) 作为辅助治疗
Lancet (London, England)
|July 26, 1980
概括
使用聚亚丁烯酸-聚尿酸 (PolyA.PolyU) 的辅助免疫疗法显著改善了可手术的乳腺癌患者的生存率. 这种无毒的治疗提高了整体和无复发的生存率,特别是在结节阳性病例中.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 辅助治疗对于改善可手术乳腺癌的结果至关重要.
- 免疫疗法提供了一种潜在的策略,可以增强身体的抗癌反应.
- 聚基-聚氨基酸 (PolyA.PolyU) 是一种免疫调节剂.
研究的目的:
- 在可手术的乳腺癌患者中评估辅助性PolyA.PolyU免疫疗法的疗效.
- 评估PolyA.PolyU对整体生存率和无复发生存率的影响.
- 为了确定PolyA.PolyU作为辅助治疗的安全性和耐受性.
主要方法:
- 一项随机对照试验,涉及300名可手术的乳腺癌患者.
- 实验组每周静脉注射30毫克PolyA.PolyU,持续6周.
- 对照组按照相同的时间表静脉注射正常盐水;随访时间>50个月.
主要成果:
- 在接受PolyA.PolyU治疗的组中,整体存活率显著更高 (p ≤0.05).
- 在接受治疗的组中观察到5年无复发存活率的增加.
- 节点阳性患者的复发率改善 (p ≤0.03) 和整体存活率 (p ≤0.07).
结论:
- 用PolyA进行辅助免疫疗法.PolyU是可手术乳腺癌的有效治疗方法.
- PolyA.PolyU 显示出良好的安全性,没有任何副作用.
- 这种免疫疗法是一种简单,无毒,高效的辅助疗法.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


